541096 — Bharat Parenterals Balance Sheet
0.000.00%
- IN₹8.39bn
- IN₹9.60bn
- IN₹3.40bn
Annual balance sheet for Bharat Parenterals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 468 | 349 | 89.3 | 109 | 680 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 762 | 806 | 1,289 | 1,791 | 1,718 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,480 | 1,437 | 1,843 | 2,599 | 3,555 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 438 | 654 | 1,402 | 2,334 | 2,291 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,986 | 2,261 | 3,503 | 5,038 | 6,485 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 436 | 415 | 1,198 | 1,904 | 2,193 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 548 | 602 | 1,675 | 3,066 | 3,179 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 1,439 | 1,658 | 1,828 | 1,973 | 3,307 |
Total Liabilities & Shareholders' Equity | 1,986 | 2,261 | 3,503 | 5,038 | 6,485 |
Total Common Shares Outstanding |